Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 31, 2022, serves as a current report for Vivos Therapeutics, Inc., a Delaware corporation. The filing announces the issuance of a press release detailing financial results for the quarter and fiscal year ended December 31, 2021. The company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No specific material changes versus prior periods are quantified in this document. The filing solely references the announcement of results for the period ended December 31, 2021.
Guidance, Outlook, and Risks
The document does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information in this report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that Section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2022) for actual financial figures for Q4 and FY 2021.
- Verify the company's cash position and burn rate given its status as an emerging growth company.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the referenced press release.
- Check for any subsequent filings that may incorporate the press release by reference for liability purposes.